跳轉至內容
Merck
全部照片(1)

重要文件

SML3839

Sigma-Aldrich

Danirixin

≥98% (HPLC)

同義詞:

3-{4-Chloro-2-hydroxy-3-[(3S)-piperidine-3-sulfonyl]phenyl}-1-(3-fluoro-2-methylphenyl)urea, GSK 1325756, GSK 1325756B, GSK-1325756, GSK-1325756B, GSK1325756, GSK1325756B, N-[4-Chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N′-(3-fluoro-2-methylphenyl)urea

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C19H21ClFN3O4S
CAS號碼:
分子量::
441.90
分類程式碼代碼:
51111800
分類程式碼代碼:
12352200
NACRES:
NA.21
暫時無法取得訂價和供貨情況

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear (Warmed)

儲存溫度

-10 to -25°C

SMILES 字串

O=C(NC1=CC=C(C(S([C@H]2CCCNC2)(=O)=O)=C1O)Cl)NC3=C(C(F)=CC=C3)C

InChI 密鑰

NGYNBSHYFOFVLS-LBPRGKRZSA-N

生化/生理作用

Danirixin (GSK1325756) is an orally active, selective CXC chemokine receptor 2 (CXCR2) antagonist with 78-fold lower affinity toward CXCR1 (CXCR2/CXCR1 IC50 = 12.5/977 nM by competitive binding against 0.225 nM [125I] CXCL8). Danirixin blocks agonist-induced neutrophil CD11b expression in vitro (IC50 = 420/890 nM against induction by 10 nM human CXCL1/rat CXCL2 using rat/human whole blood) and prevents lung neutrophils influx in rats in vivo following aerosol lipopolysaccharide or ozone challenge (ED50 = 1.4 and 16 mg/kg, respectively).
Orally active, selective CXC chemokine receptor 2 (CXCR2) antagonist.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Gang Nie et al.
International immunopharmacology, 95, 107153-107153 (2021-03-08)
Breast cancer is the most frequent cancer among females and the second most common cause of cancer deaths worldwide. Tumor-associated macrophages (TAMs) are the most abundant immune cell population in the tumor microenvironment, including breast cancer. Breast cancer stem cells
Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2
Journal of Pharmacology and Experimental Therapeutics, 362(2), 338-346 (2017)
CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin.
ERJ open research, 6(4), 00583-2020 (2020)

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務